The Detection of Hypercoagulability in Patients with Acute Cerebral Infarction Using a Clot Waveform Analysis

Figures

• 

  Figure 1.. CWA-sTF/FIXa and APTT in acute cerebral infarction (ACI) patients without anticoagulant therapy, control group without ACI, and healthy volunteers. Derivative peak times of CWA-APTT (A); derivative peak heights of CWA-APTT (B); derivative peak times of CWA-sTF/FIXa (C); derivative peak heights of CWA-sTF/FIXa (d). APTT, activated partial thromboplastin time; sTF/FIXa, small amount of tissue factor-induced FIX activation; FFT, fibrin formation time; FFH, fibrin formation height; 1stDPT, first derivative peak time; 1stDPH, first derivative peak height; second DPT, second derivative peak time; second DPH, second derivative peak height; HV, healthy volunteer; ACI (-), control group without ACI; ACI (+), ACI patients.

• 

  Figure 2.. A receiver operating characteristic analysis regarding the diagnosis of acute cerebral infarction ACI without anticoagulant versus control group without ACI using 1stDPT (A) and 1stDPH (B) of CWA-APTT and 1stDPT (C) and 1stDPH (D) of CWA-sTF/FIXa. CWA, clot waveform analysis; APTT, activated partial thromboplastin time; sTF/FIXa, small amount of tissue factor-induced FIX activation; 1stDPT, first derivative peak time; 1stDPH, first derivative peak height; second DPT, second derivative peak time; second DPH, second derivative peak height.

• 

  Figure 3.. CWA-APTT in patients with acute cerebral infarction treated with argatroban and anti-platelet agents (A), direct oral anticoagulant (B), heparin (C), or anti-platelet agents (D). CWA, clot wave form; APTT, activated partial thromboplastin time; navy line, fibrin formation curve; FFH, fibrin formation height; pink line, first derivative curve (velocity); 1stDPH, first derivative peak height; light blue, second derivative curve (acceleration); second DPH, second derivative peak height; solid line, patient; dotted line, healthy volunteer. The peak time of (A)-(D) is longer for the solid line (patient) than for the dotted line (healthy volunteer). The peak height of (A) is lower and that of (B)-(D) higher for the solid line (patient) than for the dotted line (healthy volunteer).

• 

  Figure 4.. CWA-sTF/FIXa in patients with acute cerebral infarction treated with argatroban and anti-platelet agents (A), direct oral anticoagulant (B), heparin (C), or anti-platelet agents (D). CWA, clot wave form; stf/FIXa, small amount of tissue factor-induced FIX activation; navy line, fibrin formation curve; FFH, fibrin formation height; pink line, first derivative curve (velocity); 1stDPH, first derivative peak height; light blue, second derivative curve (acceleration); second DPH, second derivative peak height; solid line, patient; dotted line, healthy volunteer. The peak times of (A) and (B) are longer for the solid line (patient) than for the dotted line (healthy volunteer). The peak height of (A) and (B) is slightly and of that of (B)-(D) higher for the solid line (patient) than for the dotted line (healthy volunteer).

• 

  Figure 5.. Effectiveness of anticoagulant therapy (A) and a hypo-coagulable state and hyper-coagulable state (B) on a clot waveform analysis.